The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
The decision positions Yartemlea as the first and only approved inhibitor of the lectin pathway of complement
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Harbour BioMed brings advanced antibody discovery platforms to the table
Subscribe To Our Newsletter & Stay Updated
